BPC-157
Compounded BPC-157 sourced through a licensed US pharmacy and placed inside clinician review, not a research-vendor checkout.
A compounded BPC-157 and TB-500 prescription pairing BPC-157's tissue-repair signaling with thymosin beta-4 biology in cell movement and wound closure.
From $179/month
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.
There is a particular kind of injury that is functional enough to stop being acute, but never good enough to become irrelevant. You can train on it. You can work around it. You can also tell exactly where the ceiling still is.
BPC-157 and TB-500 approach that plateau from different parts of the repair process.
Research shows BPC-157 promotes new blood-vessel growth through VEGFR2, a signaling pathway involved in angiogenesis.1 TB-500 is a compounded peptide related to thymosin beta-4, a naturally occurring protein involved in the internal scaffolding that lets cells change shape and move. In preclinical wound models, thymosin beta-4 attracts endothelial cells toward damaged tissue and accelerates wound closure,2 while research on a short actin-binding segment shows key wound-repair activity.3
One side of the story is access. The other is movement. Repair requires both the environment around damaged tissue and the cells doing the work inside it.
The combination is built around division of labor. BPC-157 has been studied in angiogenesis and tendon-cell repair models, while thymosin beta-4 research examines endothelial-cell movement and wound closure. Their different roles are the reason to consider them together.
The tendon is usable again, but the limit has not moved in months. You have spent enough time at the same plateau to stop calling it patience.
You are back in the gym or back on the road, but every session still has an asterisk. The old injury has become part of how you plan everything else.
The same spot has failed you more than once. At that point, the quality of the rebuild deserves as much attention as the original incident.
Compounded BPC-157 / TB-500 is not an FDA-approved drug product. Whether it is appropriate for you is determined by a licensed provider from your full Assessment.
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
3-month commitment
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
Two things drive the screening here. Neither finding says this preparation causes cancer. Both are why a provider screens carefully for any history of it. Both compounds are prohibited at all times by the World Anti-Doping Agency, in and out of competition, so if you are a tested athlete, say so at intake. Human safety data is limited, which is the reason this sits with a clinician rather than in a shopping cart.
If your provider determines you are not a candidate for any available treatment, any consultation fee paid will be refunded within 7–10 business days. You are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
In July 2026 an FDA advisory committee voted to recommend both of the compounds in this preparation, BPC-157 and TB-500, for pharmacy compounding. That recommendation is advisory and the agency has not yet acted on it. No compounded medication is FDA-approved, including this one. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product.
A recovery plateau is not a diagnosis and it does not come with a universal clock. Your provider looks at the tissue, the injury, how long progress has been flat, and what happens after treatment starts, then adjusts from there.
A peptide combination is only as serious as the medical system around it. Here, a licensed provider decides whether BPC-157 and TB-500 belong together in your care, and a licensed US pharmacy compounds the prescription specifically for you. The FDA has found products sold as research chemicals under false labels, some naming compounding pharmacies that do not exist, and warns they “can pose risks of serious harm” by bypassing the body’s defenses.F4 Testing has found wide variation in purity and in how much of the compound is actually in the vial. The difference is accountability before the medication ever reaches you, and someone medically responsible for what happens after it does.
Any time, before your renewal date. No phone calls required.
Compounded BPC-157 sourced through a licensed US pharmacy and placed inside clinician review, not a research-vendor checkout.
Compounded oral BPC-157 delivered directly into the digestive tract, with a clinician deciding whether capsule or injection fits the case.
A compounded three-peptide prescription that adds a distinct inflammation and comfort layer to the recovery conversation.